Full-Time
Member of Technical Staff
Computational Pathology
Ataraxis.ai
11-50 employees
AI-powered prognostic test for breast cancer
Compensation Overview
$100k - $300k/yr
New York, NY, USA
In Person
PhD
 AI & Machine Learning (1) |
|---|
Get referred to Ataraxis.ai
See people who can refer or advise you
- A PhD degree in machine learning, computer vision, or statistics.
- A passion for research, attention to detail, and the ability to drive tasks to completion.
- Strong preference is given to candidates with papers in A* conferences such as ICML, ICLR, NeurIPS, or CVPR, or in top journals.
- An excellent understanding of core machine learning concepts is required.
- Excellent knowledge of the foundations of statistics, linear algebra, probability, and machine learning is required.
- Excellent skills in Python and PyTorch are required.
- Experience in deep learning and computational pathology is required.
- Design and implement novel machine learning models and methods for computational pathology.
- Translate machine learning and statistics papers into production-ready code.
- Build robust model evaluation frameworks and monitor model performance.
- Disseminate results by co-authoring research papers and abstracts.
- Collaborate with a multidisciplinary team of engineers and scientists.
- Co-mentor junior members of the team.
- Experience in self-supervised learning, survival analysis, multi-modal learning, domain adaptation, causal inference, or model interpretability.
Ataraxis.ai creates precision medicine tools for cancer care using artificial intelligence. Its first product, Ataraxis Breast, is an AI-native prognostic test for breast cancer designed to predict patient outcomes more accurately and help doctors personalize treatment plans. Results are delivered quickly, within one business day, through a physician portal or to clinicians. The company differentiates itself by offering an AI-driven prognostic test that aims to set a new standard in molecular diagnostics rather than relying on traditional methods alone, with a focus on rapid, actionable insights for oncology. The goal is to improve how cancer treatment decisions are made by providing fast, data-driven prognostic information to physicians and healthcare providers.
Company Size
11-50
Company Stage
Series A
Total Funding
$44.8M
Headquarters
New York City, New York
Founded
2023
Get referred to Ataraxis.ai
See people who can refer or advise you
Simplify's Take
What believers are saying
- Nature Communications published validation on July 6, 2026 across 8,161 patients and 15 cohorts.
- ASCO 2026 presentations and UNIRAD secondary analyses strengthened evidence for individualized treatment benefit.
- Adoption by NCI-designated cancer centers and community clinics suggests real commercial traction.
What critics are saying
- Exact Sciences' Oncotype DX surpassed two million patients and owns guideline-backed chemo-benefit credibility.
- Agendia's MammaPrint and BluePrint keep expanding evidence, squeezing Ataraxis in early-stage breast cancer.
- Ataraxis is CLIA-dependent; any poor validation or reimbursement setback kills adoption quickly.
What makes Ataraxis.ai unique
- Ataraxis Breast CTX launched March 30, 2026 with individualized chemotherapy-benefit prediction.
- Ataraxis uses multimodal H&E slides plus clinical data, preserving tissue and avoiding extra procedures.
- CAP accreditation and California licensing in August 2026 expanded clinical access and credibility.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Growth & Insights and Company News
6 month growth
↑ 37%1 year growth
↑ 37%2 year growth
↑ 83%Ataraxis AI has raised $20.4 million in a Series A round led by AIX Ventures to commercialise its cancer treatment prediction technology. Thiel Bio, Founders Fund, Floating Point, Bertelsmann, Giant Ventures and Obvious Ventures also participated. The company previously raised $4 million in seed funding. The startup analyses high-resolution images of cancer cells using AI trained on hundreds of millions of images from thousands of patients. According to Ataraxis, its technology is 30% more accurate than current standards for breast cancer care. The funding will support the commercial launch of its first breast cancer test and expansion into other cancer types. Co-founded by Jan Witowski and NYU professor Krzysztof Geras, Ataraxis aims to help predict long-term cancer outcomes and potentially reduce unnecessary chemotherapy treatments.
Ataraxis AI has launched Ataraxis Breast CTX, an AI-powered test that estimates individualised chemotherapy benefit in breast cancer patients. The platform combines digitised pathology slides with clinical data to predict patient-level outcomes with and without adjuvant chemotherapy. The test was developed using multimodal data from over 10,000 breast cancer patients worldwide and validated across observational studies and randomised controlled trials. It has been adopted by top NCI-designated cancer centres and community clinics across the United States. Ataraxis Breast CTX uses the company's Tau causal inference layer to account for treatment selection bias. The platform aims to identify high-risk patients unlikely to benefit from chemotherapy, helping clinicians make more informed treatment decisions and potentially reduce overtreatment. The test is offered through a CLIA-certified laboratory.
Ataraxis AI has raised $20 million in Series A funding to advance its AI precision medicine platform, focusing on Ataraxis Breast for breast cancer diagnostics. Led by AIX Ventures, the round included investors like Thiel Bio and Founders Fund. The Kestrel model, central to their platform, is 30% more accurate than current standards. The funding will aid in expanding treatment capabilities and developing new AI models, with plans to launch Ataraxis Breast in the U.S. later this year.
Ataraxis, an AI precision medicine company focused on cancer diagnostics, has raised $20 million in Series A funding led by AIX Ventures. Founded by Jan Witowski and Krzysztof Geras in 2022, Ataraxis has now raised a total of $24 million in reported equity funding.
Ataraxis AI, a New York-based startup, secured $20.4 million in Series A funding led by AIX Ventures, with participation from Thiel Bio, Founders Fund, and others. The company, co-founded by Jan Witowski and Krzysztof Geras, uses AI to predict cancer progression and reduce unnecessary chemotherapy. Their breast cancer diagnosis accuracy is 30% higher than standard methods. The funds will aid in expanding to other cancer types and enhancing technology.